High prevalence of long-term olfactory, gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched case-control study with one-year follow-up using a comprehensive psychophysical evaluation

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
P. Boscolo-Rizzo ◽  
T. Hummel ◽  
C. Hopkins ◽  
M. Dibattista ◽  
A. Menini ◽  
...  

Background: Using an age and gender matched-pair case-control study, we aimed to estimate the long-term prevalence of psychophysical olfactory, gustatory , and chemesthesis impairment at least one year after SARS-CoV-2 infection considering the background of chemosensory dysfunction in non-COVID-19 population. Methodology: This case-controlled study included 100 patients who were home-isolated for mildly symptomatic COVID-19 between March and April 2020. One control regularly tested for SARS-CoV-2 infection and always tested negative was matched to each case according to gender and age. Chemosensory function was investigated by a comprehensive psychophysical evaluation including ortho- and retronasal olfaction and an extensive assessment of gustatory function. Differences in chemosensory parameters were evaluated through either Fisher’s exact test or Kruskal-Wallis test. Results: The psychophysical assessment of chemosensory function took place after a median of 401 days from the first SARS-CoV-2 positive swab. The evaluation of orthonasal smell identified 46% and 10% of cases and controls, respectively, having olfactory dysfunction, with 7% of COVID-19 cases being functionally anosmic. Testing of gustatory function revealed a 27% of cases versus 10% of controls showing a gustatory impairment. Nasal trigeminal sensitivity was significantly lower in cases compared to controls. Persistent chemosensory impairment was associated with emotional distress and depression. Conclusion: More than one year after the onset of COVID-19, cases exhibited an excess of olfactory, gustatory , and chemesthesis disturbances compared to matched-pair controls with these symptoms being associated to emotional distress and depression.

2021 ◽  
pp. 71-72
Author(s):  
S Mahaboob Fayaz

INTRODUCTION: Metformin is considered as the main drug of choice for the patients of type 2 diabetes mellitus. GI intolerance is a most common side effect seen in patients with long-term metformin therapy. Vitamin B12 deciency can be a consequence of metformin therapy due to malabsorption. In this study we sought to estimate vitamin B12 levels in patients who were on metformin therapy. MATERIALAND METHODS: The study is a case control study. 30 patients were on Metformin for more than one year (CASES) and the other 30 were on other anti-diabetic drugs and/or insulin for more than one year (CONTROLS). Serum vitamin B12 levels were measured by radioimmunoassay method. RESULT:In regard to vitamin B12 levels, this study clearly shows a decrease associated with Metformin therapy. CONCLUSION: Type 2 diabetics on long term Metformin therapy were found to have signicantly low levels of Vitamin B12 when compared to type 2 diabetics on other anti-diabetic drugs. Hence Vitamin B12 supplementation should be considered in patients with long term metformin therapy.


Author(s):  
César Fernández-de-las-Peñas ◽  
Juan Torres-Macho ◽  
Maria Velasco-Arribas ◽  
Jose A. Arias-Navalón ◽  
Carlos Guijarro ◽  
...  

2017 ◽  
Vol 218 (2) ◽  
pp. 239-248 ◽  
Author(s):  
Konstantia Angelidou ◽  
Peter W Hunt ◽  
Alan L Landay ◽  
Cara C Wilson ◽  
Benigno Rodriguez ◽  
...  

Vaccine ◽  
2021 ◽  
Author(s):  
Jacques Pépin ◽  
Annie-Claude Labbé ◽  
Alex Carignan ◽  
Marie-Elise Parent ◽  
Jennifer Yu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document